HUMA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
HUMA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Total Revenue Growth Rate (Future 3Y To 5Y Est) is the average growth rate of total revenue estimates over a 3-year to 5-year period.
As of today, Humacyte's Total Revenue Growth Rate (Future 3Y To 5Y Est) is N/A.
For the Biotechnology subindustry, Humacyte's Total Revenue Growth Rate (Future 3Y To 5Y Est), along with its competitors' market caps and Total Revenue Growth Rate (Future 3Y To 5Y Est) data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Humacyte's Total Revenue Growth Rate (Future 3Y To 5Y Est) distribution charts can be found below:
* The bar in red indicates where Humacyte's Total Revenue Growth Rate (Future 3Y To 5Y Est) falls into.
Humacyte (NAS:HUMA) Total Revenue Growth Rate (Future 3Y To 5Y Est) Explanation
Total Revenue Growth Rate (Future 3Y To 5Y Est) is the growth rate of total revenue estimates over a 3-year to 5-year period. This data is provided directly by our trusted data vendors Refinitiv or Morningstar.
In situations where both vendors do not directly provide the growth rate data, we use the most recent annual revenue for the current year and estimated future revenue figures provided by the vendor to calculate the growth rate. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average total revenue estimates growth rate.
Thank you for viewing the detailed overview of Humacyte's Total Revenue Growth Rate (Future 3Y To 5Y Est) provided by GuruFocus.com. Please click on the following links to see related term pages.
Laura E Niklason | director, 10 percent owner, officer: President, CEO and Director | 35 WILSHIRE ROAD, GREENWICH CT 06831 |
Brady W Dougan | director, 10 percent owner | 35 WILSHIRE ROAD, GREENWICH CT 06831 |
Ayabudge Llc | 10 percent owner | 35 WILSHIRE ROAD, GREENWICH CT 06831 |
Heather Ledbetter Prichard | officer: Chief Operating Officer | 820 BROWNWICH STREET, WAKE FOREST NC 27587 |
Michael T. Constantino | director | C/O 9 METERS BIOPHARMA, INC., 8480 HONEYCUTT ROAD, SUITE 120, RALEIGH NC 27615 |
Dale A. Sander | officer: CFO & CCDO | 11304 EMPIRE LAKES DRIVE, RALEIGH NC 27617 |
William John Scheessele | officer: Chief Commercial Officer | 620 WADE AVENUE, UNIT 501, RALEIGH NC 27605 |
Yang Cao | officer: Chief Regulatory Officer | 12 DOGLEG LANE, LAWRENCE NJ 08648 |
Charles Bruce Green | director | 3185 SCENIC DRIVE, NAPA CA 94558 |
Gordon M Binder | director | 225 S. LAKE AVE., SUITE 300, PASADENA CA 91101 |
Diane Seimetz | director | JUTASTRASSE, MUNICH 2M 80636 |
Shamik J Parikh | officer: Chief Medical Officer | 1160 HEDGEROW DRIVE, GARNET VALLEY PA 19060 |
Rajiv Shukla | director | EMERALD VIEW SUITE 400, 2054 VISTA PARKWAY, WEST PALM BEACH FL 33411 |
William Edward Tente | officer: Chief Regulatory Officer | 90 DAVIS STREET, SEEKONK MA 02771 |
Todd Pope | director | C/O TRANSENTERIX, 635 DAVIS DRIVE, SUITE 300, MORRISVILLE NC 27713 |
From GuruFocus
By sperokesalga sperokesalga • 05-04-2023
By Marketwired • 09-11-2023
By Marketwired • 09-12-2023
By Marketwired • 08-07-2023
By GuruFocus Research • 05-28-2023
By sperokesalga sperokesalga • 02-27-2023
By sperokesalga sperokesalga • 05-09-2023
By Stock market mentor Stock market mentor • 01-24-2023
By Marketwired • 09-18-2023
By GuruFocus Research GuruFocus Editor • 12-20-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.